Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia

[1]  I. MacDonald,et al.  Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience. , 2018, American journal of ophthalmology.

[2]  A. Farmery,et al.  First-in-human study of the safety and viability of intraocular robotic surgery , 2018, Nature Biomedical Engineering.

[3]  R. MacLaren,et al.  The Biological Activity of AAV Vectors for Choroideremia Gene Therapy Can Be Measured by In Vitro Prenylation of RAB6A , 2018, Molecular therapy. Methods & clinical development.

[4]  K. Xue,et al.  Retinal Degeneration in Choroideremia follows an Exponential Decay Function. , 2018, Ophthalmology.

[5]  K. Xue,et al.  Characterizing the Natural History of Visual Function in Choroideremia Using Microperimetry and Multimodal Retinal Imaging , 2017, Investigative ophthalmology & visual science.

[6]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[7]  K. Xue,et al.  Technique of retinal gene therapy: delivery of viral vector into the subretinal space , 2017, Eye.

[8]  N. Bressler,et al.  Measurement and Reproducibility of Preserved Ellipsoid Zone Area and Preserved Retinal Pigment Epithelium Area in Eyes With Choroideremia. , 2017, American journal of ophthalmology.

[9]  J. Bennett.  Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Emily S. Charlson,et al.  Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study. , 2017, Ophthalmology.

[11]  K. Xue,et al.  Structural and Functional Recovery Following Limited Iatrogenic Macular Detachment for Retinal Gene Therapy , 2017, JAMA ophthalmology.

[12]  R. MacLaren,et al.  Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina , 2016, Molecular therapy. Nucleic acids.

[13]  L. Reznicek,et al.  Structure-function relationship between Heidelberg Retina Tomography (HRT) and Heidelberg Edge Perimeter (HEP) parameters in glaucoma suspects , 2016 .

[14]  Susan M. Downes,et al.  A Qualitative and Quantitative Assessment of Fundus Autofluorescence Patterns in Patients With Choroideremia , 2016, Investigative ophthalmology & visual science.

[15]  A. V. Cideciyan,et al.  Visual Function and Central Retinal Structure in Choroideremia. , 2016, Investigative ophthalmology & visual science.

[16]  K. Xue,et al.  Correlation of Optical Coherence Tomography and Autofluorescence in the Outer Retina and Choroid of Patients With Choroideremia , 2016, Investigative ophthalmology & visual science.

[17]  G. Holder,et al.  Visual Acuity after Retinal Gene Therapy for Choroideremia. , 2016, The New England journal of medicine.

[18]  W. Hauswirth,et al.  Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial , 2016, Human Genetics.

[19]  R. MacLaren,et al.  Correlation of retinal structure and function in choroideremia carriers. , 2015, Ophthalmology.

[20]  L. Vandenberghe.  What Is Next for Retinal Gene Therapy? , 2015, Cold Spring Harbor perspectives in medicine.

[21]  Jennifer K. Sun,et al.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.

[22]  R. MacLaren,et al.  Gene therapy for choroideremia using an adeno-associated viral (AAV) vector. , 2015, Cold Spring Harbor perspectives in medicine.

[23]  J. Sahel,et al.  Clinical characteristics and current therapies for inherited retinal degenerations. , 2015, Cold Spring Harbor perspectives in medicine.

[24]  J. Bennett,et al.  Visual Psychophysics and Physiological Optics High-Resolution Adaptive Optics Retinal Imaging of Cellular Structure in Choroideremia , 2014 .

[25]  R. MacLaren,et al.  Evaluation of an Optimized Injection System for Retinal Gene Therapy in Human Patients. , 2014, Human gene therapy methods.

[26]  F. Cremers,et al.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial , 2014, The Lancet.

[27]  W. Hauswirth,et al.  A comprehensive review of retinal gene therapy. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  U. Schmidt-Erfurth,et al.  The influence of cortical, nuclear, subcortical posterior, and mixed cataract on the results of microperimetry , 2011, Eye.

[29]  Michael J. Castle,et al.  Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey , 2011, Science Translational Medicine.

[30]  Alexander Sumaroka,et al.  Vision 1 year after gene therapy for Leber's congenital amaurosis. , 2009, The New England journal of medicine.

[31]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[32]  A. J. Roman,et al.  Remodeling of the human retina in choroideremia: rab escort protein 1 (REP-1) mutations. , 2006, Investigative ophthalmology & visual science.

[33]  T. Aleman,et al.  Macular pigment and lutein supplementation in choroideremia. , 2002, Experimental eye research.

[34]  M. Brown,et al.  Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. , 1993, Science.

[35]  F. Cremers,et al.  Cloning of a gene that is rearranged in patients with choroideraemia , 1990, Nature.

[36]  S. Shapiro,et al.  An Analysis of Variance Test for Normality (Complete Samples) , 1965 .